Posts by WGNV

Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials. White RG, Churchyard GJ, Horton KC, Fiore-Gartland A, Behr MA, Clark RA, Cobelens F, Ernst JD, Esmail H, Garcia-Basteiro AL, Hadinegoro SR, Hanekom WA, Hatherill M, Hill PC, Muloiwa R, Pelzer…

Diagnostic potential of recombinant Mycobacterium tuberculosis PcaA antigen and its enhancement of protective efficacy as a subunit vaccine booster following BCG priming. Xu Y, Wang X, Zhong Q. J Microbiol Methods. 2025 Sep;236:107202. doi: 10.1016/j.mimet.2025.107202. Epub 2025 Jul 26.  CD4+ tissue-resident memory T cells and their role in immunity. Kirkby M, Veldhoen M. Immunol Cell Biol. 2025 Sep;103(8):809-819. doi: 10.1111/imcb.70052. Epub 2025 Jul 25.   The potential impact, cost and cost-effectiveness of tuberculosis interventions –…

Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E-4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial. Dagnew AF, Han LL, Naidoo K, Fairlie L, Innes JC, Middelkoop K, Tameris M, Wilkinson RJ, Ananworanich J, Bower D, Schlehuber L, Frahm N, Cinar A, Dunne M, Schmidt AC. Lancet HIV.…

Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting. Tameris M, Rozot V, Imbratta C, Geldenhuys H, Mendelsohn SC, Kany Luabeya AK, Shenje J, Tredoux N, Fisher M, Mulenga H, Bilek N, Young C, Veldsman A, Botes N, Thole J, Fritzell B, Mukherjee R,…